Neovasc Inc (NASDAQ:NVCN) Expected to Post Earnings of -$0.89 Per Share

Analysts expect Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) to report ($0.89) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Neovasc’s earnings. The highest EPS estimate is ($0.63) and the lowest is ($1.14). Neovasc reported earnings per share of ($1.50) in the same quarter last year, which would suggest a positive year-over-year growth rate of 40.7%. The business is scheduled to report its next earnings report on Thursday, March 19th.

On average, analysts expect that Neovasc will report full year earnings of ($3.35) per share for the current fiscal year. For the next fiscal year, analysts expect that the company will report earnings of ($2.45) per share, with EPS estimates ranging from ($3.54) to ($1.36). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Neovasc.

Several research analysts have weighed in on the stock. HC Wainwright set a $9.00 price target on shares of Neovasc and gave the stock a “buy” rating in a research report on Monday, November 4th. ValuEngine upgraded shares of Neovasc from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 31st. Finally, Zacks Investment Research downgraded shares of Neovasc from a “buy” rating to a “hold” rating in a research report on Wednesday, January 8th.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kessler Investment Group LLC bought a new position in Neovasc in the fourth quarter worth approximately $39,000. Virtu Financial LLC bought a new position in Neovasc in the fourth quarter worth approximately $72,000. Finally, Magnetar Financial LLC raised its position in Neovasc by 15.5% in the fourth quarter. Magnetar Financial LLC now owns 555,275 shares of the medical equipment provider’s stock worth $3,004,000 after acquiring an additional 74,349 shares during the period. Institutional investors and hedge funds own 11.45% of the company’s stock.

NVCN traded down $0.04 during trading on Tuesday, hitting $2.61. The company’s stock had a trading volume of 99,763 shares. Neovasc has a one year low of $2.34 and a one year high of $8.65. The business’s 50 day simple moving average is $3.24 and its 200-day simple moving average is $3.27.

Neovasc Company Profile

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.

Recommended Story: Most Active Stocks

Get a free copy of the Zacks research report on Neovasc (NVCN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit